Cytori Therapeutics (CYTX) Reports In-Line Q4 EPS

Cytori Therapeutics (NASDAQ: CYTX) reported Q4 EPS of ($0.08), in-line with the analyst estimate of ($0.08). Revenue for the quarter came in at $2.47 million versus the consensus estimate of $3.1 million.

For earnings history and earnings-related data on Cytori Therapeutics (CYTX) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Empire Petroleum posts $11.1M revenue in Q2 2026, narrows net loss
• LeonaBio, Inc. (LONA) Tops Q2 EPS by 32c